Navigate this market better. Subscribe for FREE stock alerts and information.

Wednesday, May 7, 2014

Allergan profit, sales top estimates; says weighing Valeant offer, (NYSE: AGN), (NYSE: TRI), (TSE: TRI.TO), (NYSE: VRX), (TSE: VRX.TO)

Allergan Inc reported better-than-expected first- quarter profit on strong sales of Botox and medical devices, and said it was reviewing an unsolicited $47 billion takeover bid from Valeant Pharmaceuticals International Inc. In its quarterly report, Allergan noted it has in place a one-year stockholder rights plan, commonly called a poison pill, meant to give the company more time to weigh the offer.Allergan said on Wednesday it earned $257 million, or 85 cents per share, in the quarter. That compared with $12.5 million, or 4 cents, in the year-earlier period, when it took a big charge for discontinued operations.Excluding special items, Allergan earned $1.18 per share in the recent quarter. Analysts, on average, expected $1.13 per share, according to Thomson Reuters I/B/E/S.Global sales rose 13 percent to $1.62 billion, topping Wall Street expectations of $1.60 billion.

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.37% or $0.62/share to $166.94. In the past year, the shares have traded as low as $81.33 and as high as $170.05. On average, 3976360 shares of AGN exchange hands on a given day and today's volume is recorded at 181182.

Thomson Reuters Corporation (Thomson Reuters), is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.03% or $0.01/share to $35.37. In the past year, the shares have traded as low as $31.38 and as high as $38.73. On average, 869666 shares of TRI exchange hands on a given day and today's volume is recorded at 99677.

Thomson Reuters Corporation (Thomson Reuters), is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.31% or $0.12/share to $38.58. In the past year, the shares have traded as low as $33.08 and as high as $42.10. On average, 929705 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 19777.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.84% or $1.12/share to $134.47. In the past year, the shares have traded as low as $72.25 and as high as $153.10. On average, 2631170 shares of VRX exchange hands on a given day and today's volume is recorded at 73066.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 1.0% or $1.45/share to $146.53. In the past year, the shares have traded as low as $72.59 and as high as $170.45. On average, 390633 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 19213.



Source